Third Harmonic IPO could signal a reopening window for NASDAQ listings

Third Harmonic’s encouraging double-digit gain after pricing its upsized IPO will likely inspire confidence among other biotechs seeking to go public on NASDAQ, after a prolonged slow season in which few companies in the sector attempted to list.

In a closely watched offering that could prompt others to follow suit, Third Harmonic Bio Inc. (NASDAQ:THRD) raised $185.3 million through the sale of 10.9 million shares at $17, the midpoint of its proposed $16-$18 range. The biotech had upsized the offering from a proposed 9 million shares...